Share on StockTwits

Adamis Pharmaceuticals Corp (NASDAQ:ADMP) Director William C. Denby purchased 2,500 shares of Adamis Pharmaceuticals Corp stock in a transaction that occurred on Tuesday, September 2nd. The shares were purchased at an average cost of $5.06 per share, with a total value of $12,650.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Shares of Adamis Pharmaceuticals Corp (NASDAQ:ADMP) traded down 4.73% during mid-day trading on Wednesday, hitting $4.83. The stock had a trading volume of 340,610 shares. Adamis Pharmaceuticals Corp has a 1-year low of $2.62 and a 1-year high of $11.90. The stock has a 50-day moving average of $3.77 and a 200-day moving average of $5.24. The company’s market cap is $50.7 million.

Separately, analysts at CRT Capital reiterated a “positive” rating on shares of Adamis Pharmaceuticals Corp in a research note on Tuesday, June 24th. They now have a $15.00 price target on the stock.

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), formerly Cellegy Pharmaceuticals, Incoperates through its wholly owned subsidiaries Cellegy Holdings, Inc, Adamis Corporation and Biosyn, Inc Adamis Corporation has two wholly owned subsidiaries: Adamis Viral Therapies, Inc (Adamis Viral) and Adamis Laboratories, Inc (Adamis Labs).

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.